AI Platforms for Biotech and Pharmaceutical Equity Research
An equity-research update should explain what changed in the evidence and how that affects the analyst’s assumptions. AI can support document retrieval and structured comparison. The analyst still needs to decide whether the new information changes a development, commercial or financing scenario.
This guide covers an earnings or clinical-readout update for a public biotech company. Maven Bio publishes the guide and is included below. Product descriptions reflect official public materials, not independent tests or a performance ranking.
Separate the four parts of the update
| Task | Evidence or output | Analyst responsibility |
| Retrieve disclosures | Original filing, earnings release, presentation or trial result | Confirm publication time and whether the source is final or preliminary |
| Assess clinical change | Study design, population, endpoint, comparator and follow-up | Judge relevance, limitations and comparability |
| Update financial inputs | Historical revenue, cash, expenses and guidance | Preserve units, reporting period and accounting definitions |
| Revise valuation assumptions | Documented scenario changes and sensitivities | Choose assumptions and explain uncertainty |
Selected tools by documented role
Maven Bio describes source-backed research and structured analysis for investment teams. Evaluate it for connecting a new clinical or company disclosure to the relevant asset landscape and investment criteria.
Maven Bio investment research description
Daloopa documents source-linked financial data, an Excel add-in and APIs. Evaluate it for updating historical model inputs. Test company-specific measures, restatements and period labels on a model you already understand.
Aiera documents access to event transcripts, filings and other financial research, with entitlements and API integrations. Evaluate it for the disclosure-monitoring component. Confirm the exact events, document versions and source rights available to your team.
Evaluate Pharma documents product forecasts and pipeline context. Evaluate it when you need a dated consensus comparison for a revised commercial assumption. A consensus estimate is an input to challenge, not a substitute for your own scenario.
Evaluate Pharma product description
The SEC’s EDGAR search provides public company filings and can serve as a direct verification route for disclosed financial facts. Access to a filing does not verify an AI system’s extraction or interpretation of it.
Write a change log before a thesis
For each potentially material change, record the prior statement, the new statement, both source dates and the affected model assumption. Distinguish management guidance from achieved results. Record an expected catalyst as an expectation until an authoritative source confirms the event.
For a clinical result, preserve the analysis population and endpoint definition. An apparent difference from a competitor’s study may reflect a different patient population, comparator or follow-up. Ask the scientific reviewer whether the comparison supports the proposed conclusion before using it to justify a market-share change.
For a financial result, retain currency, quarter versus year-to-date basis, and gross versus net or partner-share treatment. Recompute derived growth rates from the cited inputs. Keep historical actuals separate from management guidance, consensus and the analyst’s own forecast.
Evaluate a tool on a known research update
Choose an old update for which your team has the original sources and final reviewed model. Ask the tool to extract changed facts and propose a source-linked change log. Score missing material disclosures, wrong periods or units, unsupported claims and analyst correction time.
Include a case where the evidence does not justify changing the thesis. The system should be able to report uncertainty instead of producing a confident new recommendation because a fresh document appeared.
Keep investment banking as a separate workflow
An equity analyst updates a public-market thesis and scenarios. A transaction team may need a buyer shortlist, a licensing-rights assessment, a data-room question list and review of confidential documents. Those deliverables share research inputs, but the transaction team needs to evaluate rights, terms and confidential evidence as part of its mandate.
Read the life-sciences investment-banking workflow
Take one earnings update or readout to a demonstration and ask the vendor to show the source, extracted field and affected assumption. Your team can then judge the research trail before deciding whether to use the output in a model.